pharma news

News

Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare kidney disease FSGS.

News

Revolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib.

News

The last few days have seen a flurry of biotech IPO news, with Alamar, Hemab, Kailera, and Seaport all pushing for Nasdaq listings.

News

Servier $210m bet on IDEAYA's uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.

News

An AI tool could identify colorectal cancer patients most likely to respond to bevacizumab, which was recently backed for NHS use.

News

AstraZeneca's hyperkalaemia drug Lokelma could see its use by the NHS more than double thanks to updated guidance from NICE.